

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elizabeth M. Denholm, Elizabeth Cauchon, and Paul J. Silver

Serial No.: Continuation of 09/727,873 Art Unit: Not Yet Assigned

Filed: July 18, 2003 Examiner: Not Yet Assigned

For: ***ATTENUATION OF FIBROBLAST PROLIFERATION***

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including five (5) pages of Form PTO-1449. All of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/727,873, filed December 1, 2000, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S.S.N.: Continuation of 09/727,873
Filed: July 18, 2003
INFORMATION DISCLOSURE STATEMENT

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,695,752	12-09-1997	Rosen et al.	424/94.61
5,985,582	11-16-1999	Triscott	435/7.1
6,153,187	11-28-2000	Yacoby-Zeevi	424/94.5

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 95/13091 A1	05-18-1995	International Technology Management Associates, Ltd.	PCT
WO 96/01894 A1	01-25-1996	Ibex Technologies	PCT
WO 98/46258 A2	10-22-1998	Research & Development, Inc.	PCT
WO 99/484778 A1	09-30-1999	Beth Israel Deaconess Medical Center, Inc.	PCT
		Insight Strategy & Marketing Ltd.	PCT

Publications

BENSADOUN, et al. "Proteoglycan deposition in pulmonary fibrosis," *Amer. J. Respir. Crit. Care Med.* 154:1819-1828 (1996).

DENHOLM & PHAN, "The effects of bleomycin on alveolar macrophage growth factor secretion," *Amer. J. Pathol.* 134:355-363 (1989).

DENHOLM, "Inhibition of fibroblast proliferation by Chondroitinase AC(CAC) and Chondroitinase B(CB)," *FASEB J* 12(5):A948 (1998).

DENHOLM, et al., "Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate," *European Journal of Pharmacology* 400:145-153 (2000).

DONATI, et al., "Treatment of hypertrophic and keloid cicatrices with thiomucase," *Minerva Chirurgica* 30(6):326-33 AN-Medline 76196588 (1975).

FANNON & NUGENT, "Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate," *J. Biol. Chem.* 271:17949-17956 (1996).

FORRESTER, et al., "A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies," *J. Am. Coll. Cardiol.* 17:758-769 (1991).

U.S.S.N.: Continuation of 09/727,873
Filed: July 18, 2003
INFORMATION DISCLOSURE STATEMENT

JACKSON, et. al., "Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes," *Physiol. Rev.* 71:481-530 (1991).

KELLER, et al., "Modulation of cell surface heparan sulfate structure by growth of cells in the presence of chlorate," *Biochem.* 28:8100-8107 (1989).

KJELLÉN & LINDAHL, "Proteoglycans: structures and interactions," *Ann. Rev. Biochem.* 60:443-475 (1991).

LINHARDT, et al., "Polysaccharide lyases," *Appl. Biochem. Biotech.* 12:135-175 (1986).

LINN, et al. "Isolation and characterization of two chondroitin lyases from *Bacteroides thetaiotaomicron*," *J. Bacteriol.* 156:859-866 (1983).

LIU & CONNOLLY, "Isolation and characterization of two chondroitin lyases from *Bacteroides thetaiotaomicron*," *Sem. Cutaneous Med. and Surg.* 17:3-11 (1998).

LYON, et al., "Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate," *J. Biol. Chem.* 273:271-278 (1998).

MAEDA, et al., "6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTP β , binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)," *J. Biol. Chem.* 271:21446-21452 (1996).

MIAO, et al., "Heparan sulfate primed on beta-D-xylosides restores binding of basic fibroblast growth factor," *J. Cell. Biochem.* 57:173-184 (1995).

MICHELACCI, et. al., "Isolation and characterization of an induced chondroitinase ABC from *Flavobacterium heparinum*," *Biochim. Biophys. Acta.* 923:291-201 (1987).

MILEV, et al., "The core protein of the chondroitin sulfate proteoglycan phosphacan is a high-affinity ligand of fibroblast growth factor-2 and potentiates its mitogenic activity," *J. Biol. Chem.* 273:21439-21442 (1998).

PENC & GALLO, "Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function," *J. Biol. Chem.* 273:28116-28121 (1998).

PHAN & KUNKEL, "Lung cytokine production in bleomycin-induced pulmonary fibrosis," *Exper. Lung Res.* 18:29-43 (1992).

RICHARDSON & HATTON, "Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing," *Exp. Mol. Pathol.* 58:77-95 (1993).

SATO, et. al., "Subunit structure of Chondroitinase ABC from *Proteus vulgaris*," *Agric. Biol. Chem.* 50:1057-1059 (1986).

U.S.S.N.: Continuation of 09/727,873

Filed: July 18, 2003

INFORMATION DISCLOSURE STATEMENT

SCHMIDT, et al., "The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2-O-sulfated uronic acid residues," *J. Biol. Chem.* 267:19242-19247 (1992).

SCHWARTZ, "Regulation of chondroitin sulfate synthesis. Effect of beta-xylosides on synthesis of chondroitin sulfate proteoglycan, chondroitin sulfate chains, and core protein," *J. Biol. Chem.* 252:6316-6321 (1977).

SEGARINI, et al., "Binding of transforming growth factor-beta to cell surface proteins varies with cell type," *Molecular Endocrinol.* 3:261-272 (1989).

SUNDBERG, et al., "Development and progression of psoriasisiform dermatitis and systemic lesions in the flaky skin (fsn) mouse mutant," *Pathobiology* 65:271-286 (1997).

TABAS, et al., "Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation," *J. Biol. Chem.* 268(27):20419-20432 (1993).

TAO, et. al., "Elevated expression of proteoglycans in proliferating vascular smooth muscle cells," *Atherosclerosis* 135:171-179 (1997).

VARANI, et al., "Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion," *Amer. J. Pathol.* 145:561-573 (1994).

VLODAVSKY, et al., "Control of cell proliferation by heparan sulfate and heparin-binding growth factors," *Thrombosis Haemostasis* 74:534-540 (1995).

YAMAGATA, et al., "Purification and properties of bacterial chondroitinases and chondrosulfatases," *J. Biol. Chem.* 243:1523-1535 (1968).

YAYON, et al., "Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor," *Cell* 64:841-848 (1991).

YEO, et al. Alterations in proteoglycan synthesis common to healing wounds and tumors," *Amer. J. Pathol.* 138:1437-1450 (1991).


ZHANG, et. al., "In situ hybridization analysis of rat lung alpha 1(I) and alpha 2(I) collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection," *Lab. Invest.* 70: 192-202 (1994).

U.S.S.N.: Continuation of 09/727,873
Filed: July 18, 2003
INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Zhaoyang Li
Reg. No. 46,872

Dated: July 18, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

ATL1 #584585 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>	<p>Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>C ntinuation of 09/727,873</td> </tr> <tr> <td>Filing Date</td> <td>July 18, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Elizabeth M. Denholm</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>IT 105 CON</td> </tr> </table>		Application Number	C ntinuation of 09/727,873	Filing Date	July 18, 2003	First Named Inventor	Elizabeth M. Denholm	Group Art Unit		Examiner Name		Attorney Docket Number	IT 105 CON
Application Number	C ntinuation of 09/727,873													
Filing Date	July 18, 2003													
First Named Inventor	Elizabeth M. Denholm													
Group Art Unit														
Examiner Name														
Attorney Docket Number	IT 105 CON													
Sheet	1	of												
	5													

U.S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Examine Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/727,873
Sheet	2	of	5
		Filing Date	July 18, 2003
		First Named Inventor	Elizabeth M. Denholm
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	IT 105 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published ^{T²}
		BENSADOUN, et al. "Proteoglycan deposition in pulmonary fibrosis," <i>Amer. J. Respir. Crit. Care Med.</i> 154:1819-1828 (1996).
		DENHOLM & PHAN, "The effects of bleomycin on alveolar macrophage growth factor secretion," <i>Amer. J. Pathol.</i> 134:355-363 (1989).
		DENHOLM, "Inhibition of fibroblast proliferation by Chondroitinase AC(CAC) and Chondroitinase B(CB)," <i>FASEB J</i> 12(5):A948 (1998).
		DENHOLM, et al., "Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate," <i>European Journal of Pharmacology</i> 400:145-153 (2000)..
		DONATI, et al., "Treatment of hypertrophic and keloid cicatrices with thiomucose," <i>Minerva Chirurgica</i> 30(6):326-33 AN-Medline 76196588 (1975).
		FANNON & NUGENT, "Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate," <i>J. Biol. Chem.</i> 271:17949-17956 (1996).
		FORRESTER, et al., "A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies," <i>J. Am. Coll. Cardiol.</i> 17:758-769 (1991).
		JACKSON, et. al., "Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes," <i>Physiol. Rev.</i> 71:481-530 (1991).
		KELLER, et al., "Modulation of cell surface heparan sulfate structure by growth of cells in the presence of chloride," <i>Biochem.</i> 28:8100-8107 (1989).
		KJELLÉN & LINDAHL, "Proteoglycans: structures and interactions," <i>Ann. Rev. Biochem.</i> 60:443-475 (1991).

Examiner's Signature:	Date Considered:
-----------------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 09/727,873
Sheet	3	of	5	Filing Date	July 18, 2003
				First Named Inventor	Elizabeth M. Denholm
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	IT 105 CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LINHARDT, et al., "Polysaccharide lyases," <i>Appl. Biochem. Biotech.</i> 12:135-175 (1986).	
		LINN, et al. "Isolation and characterization of two chondroitin lyases from <i>Bacteroides thetaiotaomicron</i> ," <i>J. Bacteriol.</i> 156:859-866 (1983).	
		LIU & CONNOLLY, "Isolation and characterization of two chondroitin lyases from <i>Bacteroides thetaiotaomicron</i> ," <i>Sem. Cutaneous Med. and Surg.</i> 17:3-11 (1998).	
		LYON, et al., "Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate," <i>J. Biol. Chem.</i> 273:271-278 (1998).	
		MAEDA, et al., "6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)," <i>J. Biol. Chem.</i> 271:21446-21452 (1996).	
		MIAO, et al., "Heparan sulfate primed on beta-D-xylosides restores binding of basic fibroblast growth factor," <i>J. Cell. Biochem.</i> 57:173-184 (1995).	
		MICHELACCI, et. al., "Isolation and characterization of an induced chondroitinase ABC from <i>Flavobacterium heparinum</i> ," <i>Biochim. Biophys. Acta</i> . 923:291-201 (1987).	
		MILEV, et al., "The core protein of the chondroitin sulfate proteoglycan phosphacan is a high-affinity ligand of fibroblast growth factor-2 and potentiates its mitogenic activity," <i>J. Biol. Chem.</i> 273:21439-21442 (1998).	
		PENC & GALLO, "Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function," <i>J. Biol. Chem.</i> 273:28116-28121 (1998).	
		PHAN & KUNKEL, "Lung cytokine production in bleomycin-induced pulmonary fibrosis," <i>Exper. Lung Res.</i> 18:29-43 (1992).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Compleat if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/727,873
Sheet	4	of	5
		Attorney Docket Number	IT 105 CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
		RICHARDSON & HATTON, "Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing," <i>Exp. Mol. Pathol.</i> 58:77-95 (1993).		
		SATO, et. al., "Subunit structure of Chondroitinase ABC from <i>Proteus vulgaris</i> ," <i>Agric. Biol. Chem.</i> 50:1057-1059 (1986).		
		SCHMIDT, et al., "The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2-O-sulfated uronic acid residues," <i>J. Biol. Chem.</i> 267:19242-19247 (1992).		
		SCHWARTZ, "Regulation of chondroitin sulfate synthesis. Effect of beta-xylosides on synthesis of chondroitin sulfate proteoglycan, chondroitin sulfate chains, and core protein," <i>J. Biol. Chem.</i> 252:6316-6321 (1977).		
		SEGARINI, et al., "Binding of transforming growth factor-beta to cell surface proteins varies with cell type," <i>Molecular Endocrinol.</i> 3:261-272 (1989).		
		SUNDBERG, et al., "Development and progression of psoriasisform dermatitis and systemic lesions in the flaky skin (fsn) mouse mutant," <i>Pathobiology</i> 65:271-286 (1997).		
		TABAS, et al., "Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation," <i>J. Biol. Chem.</i> 268(27):20419-20432 (1993).		
		TAO, et. al., "Elevated expression of proteoglycans in proliferating vascular smooth muscle cells," <i>Atherosclerosis</i> 135:171-179 (1997).		
		VARANI, et al., "Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion," <i>Amer. J. Pathol.</i> 145:561-573 (1994).		
		VLODAVSKY, et al., "Control of cell proliferation by heparan sulfate and heparin-binding growth factors," <i>Thrombosis Haemostasis</i> 74:534-540 (1995).		

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/727,873
Filing Date	July 18, 2003		
First Named Inventor	Elizabeth M. Denholm		
Group Art Unit			
Examiner Name			
Sheet	5	of	5
		Attorney Docket Number	IT 105 CON

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number

Continuation of 09/727,873

Filing Date

July 18, 2003

First Named Inventor

Elizabeth M. Denholm

Group Art Unit

Examiner Name

Sheet

5

of

5

Socket Number

IT 105 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

**Examiner's
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.